The loss of an NIH supplement at the University of Pittsburgh disrupted research on antibiotic-resistant infections and limited a key pathway for training early-career scientists.
An NIH-funded research project at the University of Pittsburgh saw the termination in early-2025 of a diversity supplement supporting financial costs for a graduate research trainee following changes to NIH diversity supplement policies. The supplement was tied to a multi-year NIH award studying how antibiotic-resistance infections evolve and persist, research with direct relevance to hospital safety and public health in the United States and globally. Although the parent award remained in place, the loss of the supplement disrupted the research team’s structure and created an unanticipated financial burden on the university.
Because universities commit upfront to financially supporting enrolled graduate students, the Department of Medicine had to step in to cover the affected student's remaining tuition and stipend costs. While this stopgap allowed the student to continue their training, redirecting these funds may limit the program's ability to admit and support future graduate students in the coming years.
These terminations also send a discouraging signal to trainees, reinforcing career uncertainty about whether scientific training and workforce development remain federal priorities. Diversity supplements historically supported students from financially disadvantaged backgrounds, as well as those from groups underrepresented in biomedical research, including rural students, individuals with disabilities, and certain racial and ethnic groups. Their elimination removes a proven NIH mechanism for both advancing high-impact medical research and strengthening the pipeline of future scientists.